Dr Michelle Brown
Postdoctoral Researcher
School of Medicine and Public Health (Medical Genetics)
- Email:michelle.wong-brown@newcastle.edu.au
- Phone:(02) 4042 0321
New hope for women with ovarian cancer
Dr Michelle Wong-Brown’s research is breaking new ground in the treatment of one of the world’s deadliest diseases: ovarian cancer.
Dr Michelle Wong-Brown’s research is contributing to a growing body of knowledge about how women with ovarian cancer respond to chemotherapy. Specifically, it looks at why some women respond poorly—or not at all— and how alternative treatments present an opportunity to improve survival rates.
Out of all cancers, ovarian cancer has one of the poorest prognoses, especially when diagnosed late. The five-year survival rate is just over 44 per cent. Many women with ovarian cancer will undergo surgery, potentially followed by chemotherapy. However, recurrence typically occurs in up to 75 per cent of patients who can then develop resistance to chemotherapy.
There is a growing body of evidence—including Michelle’s research—showing that women with ovarian cancer often display a deficiency in their DNA’s ability to repair itself following chemotherapy. Known as homologous recombination (HR) deficiency, this condition can make women resistant to chemotherapy and hinder their chances of survival.
“Currently, when a woman doesn’t respond to chemotherapy—typically because of her DNA’s inability to repair itself—she’s told that nothing further can be done. Well, that simply isn’t good enough.”
Michelle’s research is helping to turn the tide for women with ovarian cancer, creating new hope and solutions.
“My highest goal is to eradicate ovarian cancer altogether. While this might not happen in my research lifetime, there are steps we can take today towards this goal—like providing patients with treatment options that will have the best outcomes for them.”
A life-changing revelation
Michelle’s interest in understanding DNA repair pathways was piqued in 2017 by her mentor: Associate Professor Nikola Bowden.
Until that point, Michelle had been investigating BRCA genes (the body’s natural tumour suppressors), which, in their mutated form, can increase predisposition to breast cancer. Associate Professor Bowden’s research showed that DNA repair pathways, including those associated with BRCA genes, could be involved in chemotherapy resistance in ovarian cancer patients.
The revelation set Michelle’s research career on a whole new path.
“Nikola and I decided to combine our expertise, knowledge, and data to find ways to overcome this resistance and improve treatment outcomes for women with ovarian cancer.”
Trialling new solutions
Michelle’s postdoctoral research with the DNA Repair Group, based at the Hunter Medical Research Institute (HMRI), includes developing and implementing new clinical trial testing drug combinations that haven’t been used to treat ovarian cancer before.
The multi-disciplinary trial, conducted in collaboration with oncologists at the Calvary Mater, will use existing drugs that have already undergone safety and efficacy tests—meaning they can be put into practice for patients faster.
“I’m excited to become more actively involved in clinical trials. If we discover effective new drug combinations, we can give patients with no remaining treatment options another chance.”
As well as testing existing drugs in new combinations, Michelle will also trial new drugs to treat ovarian cancer by slowing or halting its growth.
“We are looking at whether these new drugs, on their own or in combination, can slow the growth, stop the growth, or kill the ovarian tumour completely.”
Michelle’s work on developing DNA repair profiles that identify HR deficiency will help oncologists determine which patients are likely to respond well to chemotherapy, allowing for more personalised, targeted treatment.
“Information about a patient’s profile can help us predict the best treatment option for them. Patients predicted to have no long-term benefit from chemotherapy, based on their expression profiles, can be spared the toxic side effects.”
Michelle was the first recipient of the HMRI Karen Brown Breast Cancer Travel Award in 2014. In 2018, she participated in the University’s ThinkWell Early and Mid-Career Women’s Development Program, facilitated through the Faculty of Health and Medicine's Gender Equity Committee.
New hope for women with ovarian cancer
Dr Michelle Wong-Brown’s research is breaking new ground in the treatment of one of the world’s deadliest diseases: ovarian cancer.
Career Summary
Biography
Dr Michelle Wong-Brown is a postdoctoral fellow with the University’s School of Medicine and Public Health and Centre for Drug Repurposing and Medicines Research (CDRMR). Her research explores the homologous recombination (HR) DNA repair pathway following chemotherapy. Resistance to further chemotherapy—caused by HR deficiency—is common in patients who experience a resurgence of ovarian cancer following surgery and initial chemotherapy. Through her research on alternative treatments, Michelle is working to restore hope to this vast cohort.
Michelle completed a Bachelor of Biomedical Science (Honours) in 2007. During her undergraduate studies, she undertook two summer scholarship projects that fed her growing interest in laboratory-based research. Following graduation, Michelle commenced work with the Molecular Genetics diagnostic laboratory, within NSW Health Pathology (previously the Hunter Area Pathology Service), where she conducted genetic tests for BRCA genes—genes that, when mutated, can increase predisposition to breast cancer. Michelle completed a PhD in this research area, before shifting her focus to DNA repair pathways in the years to follow.
Michelle’s expertise in sequencing led to her appointment as a member of the Advisory Committee of the Royal College of Pathologists Quality Assurance Program (RCPAQAP) Sanger DNA Sequencing module in 2015. She stepped into her current role with the DNA Repair Group, located within the Hunter Medical Research Institute (HMRI), in 2018.
Michelle has published numerous peer-reviewed articles in high-ranking journals, including the frequently cited article titled “BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer”. The article was one of the earliest publications to show that germline mutations in the HR gene PALB2 are involved in the genetic predisposition to familial breast cancer. It contributed to the knowledge that PALB2 should be offered for genetic testing. As a result, the HR genes BRCA1, BRCA2, and PALB2 are now screened in the genetic diagnosis of familial breast cancer.
Qualifications
- Doctor of Philosophy, University of Newcastle
- Bachelor of Biomedical Sciences, University of Newcastle
- Bachelor of Biomedical Sciences (Hons), University of Newcastle
Keywords
- BRCA mutations
- Chemotherapy
- DNA repair
- Drug repurposing
- Gene expression
- Next-generation sequencing
- Ovarian cancer
Languages
- Malay (Fluent)
- English (Mother)
Fields of Research
Code | Description | Percentage |
---|---|---|
321105 | Chemotherapy | 60 |
310509 | Genomics | 40 |
Professional Experience
UON Appointment
Title | Organisation / Department |
---|---|
Casual Lecturer | University of Newcastle School of Biomedical Sciences and Pharmacy Australia |
Academic appointment
Dates | Title | Organisation / Department |
---|---|---|
1/9/2009 - 1/9/2010 | Tutor | University of Newcastle School of Biomedical Sciences Australia |
1/8/2008 - | Research assistant | University of Newcastle Australia |
Professional appointment
Dates | Title | Organisation / Department |
---|---|---|
1/11/2008 - 1/2/2009 | Hospital scientist | Hunter Area Pathology Service Division of Genetics Australia |
Awards
Award
Year | Award |
---|---|
2014 |
HMRI Karen Brown Breast Cancer Travel Award Hunter Medical Research Institute (HMRI) |
2013 |
HCRA 2013 Translational Cancer Research Conference - Excellence in Translational Research Hunter Cancer Research Alliance (HCRA) |
2012 |
2012 Winter School in Mathematical and Computational Biology Travel Bursary Award Institute for Molecular Bioscience, The University of Queensland |
Teaching
Code | Course | Role | Duration |
---|---|---|---|
HUBS3302 |
Bioinformatics and Functional Genomics The University of Newcastle - School of Biomedical Sciences and Pharmacy |
Associate Lecturer | 1/9/2014 - 30/6/2018 |
HUBS3204 |
Advance Professional Skills in Biomedical Science The University of Newcastle - School of Biomedical Sciences and Pharmacy |
Associate Lecturer | 1/9/2014 - 30/6/2018 |
HUBS2209 |
Human Cell Biology and Cancer The University of Newcastle - School of Biomedical Sciences and Pharmacy |
Associate Lecturer | 1/9/2014 - 30/6/2018 |
Publications
For publications that are currently unpublished or in-press, details are shown in italics.
Journal article (25 outputs)
Year | Citation | Altmetrics | Link | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
2022 |
Wong-Brown M, McPhillips M, Gleeson M, Spigelman AD, Meldrum CJ, Dooley S, Scott RJ, 'When is a mutation not a mutation: the case of the c.594-2A \ C splice variant in a woman harbouring another BRCA1 mutation in trans (vol 14, 6, 2016)', HEREDITARY CANCER IN CLINICAL PRACTICE, 20 (2022)
|
||||||||||
2022 |
Wong-Brown MW, van der Westhuizen A, Bowden NA, 'Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy', BMC CANCER, 22 (2022) [C1]
|
Nova | |||||||||
2021 |
Matthews BG, Bowden NA, Wong-Brown MW, 'Epigenetic Mechanisms and Therapeutic Targets in Chemoresistant High-Grade Serous Ovarian Cancer', CANCERS, 13 (2021) [C1]
|
Nova | |||||||||
2021 |
Li N, Lim BWX, Thompson ER, McInerny S, Zethoven M, Cheasley D, et al., 'Investigation of monogenic causes of familial breast cancer: data from the BEACCON case-control study', NPJ BREAST CANCER, 7 (2021) [C1]
|
Nova | |||||||||
2020 |
Wong-Brown MW, van der Westhuizen A, Bowden NA, 'Targeting DNA Repair in Ovarian Cancer Treatment Resistance', Clinical Oncology, 32 518-526 (2020) [C1] Most patients with advanced high-grade serous ovarian cancer (HGSOC) develop recurrent disease within 3 years and succumb to the disease within 5 years. Standard treatment for HGS... [more] Most patients with advanced high-grade serous ovarian cancer (HGSOC) develop recurrent disease within 3 years and succumb to the disease within 5 years. Standard treatment for HGSOC is cytoreductive surgery followed by a combination of platinum (carboplatin or cisplatin) and taxol (paclitaxel) chemotherapies. Although initial recurrences are usually platinum-sensitive, patients eventually develop resistance to platinum-based chemotherapy. Accordingly, one of the major problems in the treatment of HGSOC and disease recurrence is the development of chemotherapy resistance. One of the causes of chemoresistance may be redundancies in the repair pathways involved in the response to DNA damage caused by chemotherapy. These pathways may be acting in parallel, where if the repair pathway that is responsible for triggering cell death after platinum chemotherapy therapy is deficient, an alternative repair pathway compensates and drives cancer cells to repair the damage, leading to chemotherapy resistance. In addition, if the repair pathways are epigenetically inactivated by DNA methylation, cell death may not be triggered, resulting in accumulation of mutations and DNA damage. There are novel and existing therapies that can drive DNA repair pathways towards sensitivity to platinum chemotherapy or targeted therapy, thus enabling treatment-resistant ovarian cancer to overcome chemotherapy resistance.
|
Nova | |||||||||
2020 |
Taylor RM, Smith R, Collins CE, Mossman D, Wong-Brown MW, Chan EC, et al., 'Global DNA methylation and cognitive and behavioral outcomes at 4 years of age: A cross-sectional study', Brain and Behavior, 10 1-11 (2020) [C1]
|
Nova | |||||||||
2019 |
Warren CFA, Wong-Brown MW, Bowden NA, 'BCL-2 family isoforms in apoptosis and cancer', Cell Death and Disease, 10 1-12 (2019) [C1]
|
Nova | |||||||||
2018 |
Taylor RM, Smith R, Collins CE, Mossman D, Wong-Brown MW, Chan EC, et al., 'Methyl-donor and cofactor nutrient intakes in the first 2 3 years and global DNA methylation at age 4: A prospective cohort study', Nutrients, 10 (2018) [C1]
|
Nova | |||||||||
2016 |
Thompson ER, Rowley SM, Li N, McInerny S, Devereux L, Wong-Brown MW, et al., 'Panel testing for familial breast cancer: Calibrating the tension between research and clinical care', Journal of Clinical Oncology, 34 1455-1459 (2016) [C1] Purpose Gene panel sequencing is revolutionizing germline risk assessment for hereditary breast cancer. Despite scant evidence supporting the role of many of these genes in breast... [more] Purpose Gene panel sequencing is revolutionizing germline risk assessment for hereditary breast cancer. Despite scant evidence supporting the role of many of these genes in breast cancer predisposition, results are often reported to families as the definitive explanation for their family history. We assessed the frequency of mutations in 18 genes included in hereditary breast cancer panels among index cases from families with breast cancer and matched population controls. Patients and Methods Cases (n= 2,000) were predominantly breast cancer-affected women referredto specialized Familial Cancer Centers on the basis of a strong family history of breast cancer and BRCA1 and BRCA2 wild type. Controls (n = 1,997) were cancer-free women from the LifePool study. Sequencing data were filtered for known pathogenic or novel loss-of-function mutations. Results Excluding 19 mutations identified in BRCA1 and BRCA2 among the cases and controls, a total of 78 cases (3.9%) and 33 controls (1.6%) were found to carry potentially actionable mutations. A significant excess of mutations was only observed for PALB2 (26 cases, four controls) and TP53 (five cases, zero controls), whereas no mutations were identified in STK11. Among the remaining genes, loss-of function mutations were rare, with similar frequency between cases and controls. Conclusion The frequency ofmutations in most breast cancer panel genes among individuals selected for possible hereditary breast cancer is low and, in many cases, similar or even lower than that observed among cancer-free population controls. Although multigene panels can significantly aid in cancer risk management and expedite clinical translation of new genes, they equally have the potential to provide clinical misinformation and harm at the individual level if the data are not interpreted cautiously.
|
Nova | |||||||||
2016 |
Easton DF, Lesueur F, Decker B, Michailidou K, Li J, Allen J, et al., 'No evidence that protein truncating variants in
|
||||||||||
2016 |
Wong-Brown M, McPhillips M, Gleeson M, Spigelman AD, Meldrum CJ, Dooley S, Scott RJ, 'When is a mutation not a mutation: the case of the c.594-2A\C splice variant in a woman harbouring another BRCA1 mutation in trans.', Hered Cancer Clin Pract, 14 6 (2016) [C1]
|
Nova | |||||||||
2016 |
Li N, Thompson ER, Rowley SM, McInerny S, Devereux L, Goode D, et al., 'Reevaluation of RINT1 as a breast cancer predisposition gene', Breast Cancer Research and Treatment, 159 385-392 (2016) [C1]
|
Nova | |||||||||
2016 |
Morten BC, Wong-Brown MW, Scott RJ, Avery-Kiejda KA, 'The presence of the intron 3 16 bp duplication polymorphism of p53 (rs17878362) in breast cancer is associated with a low 40p53:p53 ratio and better outcome', Carcinogenesis, 37 81-86 (2016) [C1] Breast cancer is the most common female cancer, but it has relatively low rates of p53 mutations, suggesting other mechanisms are responsible for p53 inactivation. We have shown t... [more] Breast cancer is the most common female cancer, but it has relatively low rates of p53 mutations, suggesting other mechanisms are responsible for p53 inactivation. We have shown that the p53 isoform, ¿40p53, is highly expressed in breast cancer, where it may contribute to p53 inactivation. ¿40p53 can be produced by alternative splicing of p53 in intron 2 and this is regulated by the formation of G-quadruplex structures in p53 intron 3, from which the nucleotides forming these structures overlap with a common polymorphism, rs17878362. rs17878362 alters p53 splicing to decrease fully spliced p53 messenger RNA (mRNA) in vitro following ionizing radiation and this in turn alters ¿40p53:p53. Hence, the presence of rs17878362 may be important in regulating ¿40p53:p53 in breast cancer. This study aimed to determine if rs17878362 was associated with altered ¿40p53 and p53 expression and outcome in breast cancer. We sequenced p53 in breast tumours from 139 patients and compared this with ¿40p53 and p53 mRNA expression. We found that the ratio of ¿40p53:p53 was significantly lower in tumours homozygous for the polymorphic A2 allele compared with those who were wild-type (A1/A1). Furthermore, there was a lower proportion of breast cancers carrying the A2 allele from patients who subsequently developed metastasis compared with those that did not. Finally, we show that patients whose tumours carried the polymorphic A2 allele had significantly better disease-free survival. These results show that rs17878362 is associated with a low ¿40p53:p53 ratio in breast cancer and that this is associated with better outcome.
|
Nova | |||||||||
2016 |
Mathe A, Wong-Brown M, Locke WJ, Stirzaker C, Braye SG, Forbes JF, et al., 'DNA methylation profile of triple negative breast cancer-specific genes comparing lymph node positive patients to lymph node negative patients', SCIENTIFIC REPORTS, 6 (2016) [C1]
|
Nova | |||||||||
2015 |
Thompson ER, Gorringe KL, Rowley SM, Wong-Brown MW, McInerny S, Li N, et al., 'Prevalence of PALB2 mutations in Australian familial breast cancer cases and controls', BREAST CANCER RESEARCH, 17 (2015) [C1]
|
Nova | |||||||||
2015 |
Wong-Brown MW, Meldrum CJ, Carpenter JE, Clarke CL, Narod SA, Jakubowska A, et al., 'Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer', Breast Cancer Research and Treatment, 150 71-80 (2015) [C1] Triple-negative breast cancers¿(TNBC) lack expression of oestrogen, progesterone and HER2 receptors. The gene expression profiles of TNBCs are similar to those of breast tumours i... [more] Triple-negative breast cancers¿(TNBC) lack expression of oestrogen, progesterone and HER2 receptors. The gene expression profiles of TNBCs are similar to those of breast tumours in women with BRCA1 mutations. Reports to date indicate that up to 20¿% of TNBC patients harbour germline BRCA mutations; however, the prevalence of BRCA mutations in TNBC patients varies widely between countries and from study to study. We studied 774 women with triple-negative breast cancer, diagnosed on average at age 58.0¿years. Samples of genomic DNA were provided by the Australian Breast Cancer Tissue Bank (ABCTB) (439 patients) and by the Department of Genetics and Pathology of the Pomeranian Medical University (335 patients). The entire coding regions and the exon¿intron boundaries of BRCA1 and BRCA2 were amplified and sequenced by next-generation sequencing. We identified a BRCA1 or BRCA2 mutation in 74 of 774 (9.6¿%) triple-negative patients. The mutation prevalence was 9.3¿% in Australia and was 9.9¿% in Poland. In both countries, the mean age of diagnoses of BRCA1 mutation carriers was significantly lower than that of non-carriers, while the age of onset of BRCA2 mutation carriers was similar to that of non-carriers. In the Australian cohort, 59¿% of the mutation-positive patients did not have a family history of breast or ovarian cancer, and would not have qualified for genetic testing. The triple-negative phenotype should be added as a criterion to genetic screening guidelines.
|
Nova | |||||||||
2015 |
Mathe A, Wong-Brown M, Morten B, Forbes JF, Braye SG, Avery-Kiejda KA, Scott RJ, 'Novel genes associated with lymph node metastasis in triple negative breast cancer', Scientific Reports, 5 (2015) [C1] Triple negative breast cancer (TNBC) is the most aggressive breast cancer subtype with the worst prognosis and no targeted treatments. TNBC patients are more likely to develop met... [more] Triple negative breast cancer (TNBC) is the most aggressive breast cancer subtype with the worst prognosis and no targeted treatments. TNBC patients are more likely to develop metastases and relapse than patients with other breast cancer subtypes. We aimed to identify TNBC-specific genes and genes associated with lymph node metastasis, one of the first signs of metastatic spread. A total of 33 TNBCs were used; 17 of which had matched normal adjacent tissues available, and 15 with matched lymph node metastases. Gene expression microarray analysis was used to reveal genes that were differentially expressed between these groups. We identified and validated 66 genes that are significantly altered when comparing tumours to normal adjacent samples. Further, we identified 83 genes that are associated with lymph node metastasis and correlated these with miRNA-expression. Pathway analysis revealed their involvement in DNA repair, recombination and cell death, chromosomal instability and other known cancer-related pathways. Finally, four genes were identified that were specific for TNBC, of which one was associated with overall survival. This study has identified novel genes involved in LN metastases in TNBC and genes that are TNBC specific that may be used as treatment targets or prognostic indicators in the future.
|
Nova | |||||||||
2015 |
Thompson ER, Gorringe KL, Rowley SM, Li N, McInerny S, Wong-Brown MW, et al., 'Reevaluation of the BRCA2 truncating allele c.9976A \ T (p.Lys3326Ter) in a familial breast cancer context', SCIENTIFIC REPORTS, 5 (2015) [C1]
|
Nova | |||||||||
2014 |
Wong-Brown MW, Avery-Kiejda KA, Bowden NA, Scott RJ, 'Low prevalence of germline PALB2 mutations in Australian triple-negative breast cancer', International Journal of Cancer, 134 301-305 (2014) [C1] Triple-negative breast cancer (TNBC) is a tumour classification that is defined by oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 receptor ... [more] Triple-negative breast cancer (TNBC) is a tumour classification that is defined by oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 receptor negativity. TNBCs share a similar gene expression profile to BRCA-mutated tumours, have been shown to carry a high proportion of BRCA mutations and have a more adverse prognosis compared to other types of breast tumours. PALB2 has been shown to be a moderate-penetrance breast cancer susceptibility gene and is involved in the same DNA damage repair pathway as BRCA1 and BRCA2; this raises the possibility that germline PALB2 mutations may be involved in the pathogenesis of TNBCs. In our study, we sequenced the coding regions of PALB2 (including intron/exon boundaries) in genomic DNA from 347 patients diagnosed with TNBC to determine the prevalence of deleterious mutations in this population. Two novel truncating mutations (c.758dup and c.2390del) and one previously detected truncating mutation (c.3113+5G>C) were found. In addition, five variants predicted to be protein-affecting were also identified. Our study shows that the prevalence of PALB2 germline mutations in individuals with TNBC is ~1%, similar to the prevalence of PALB2 germline mutation of 1% in familial non-BRCA1/2 breast cancer cohorts. © 2013 UICC.
|
Nova | |||||||||
2014 |
Avery-Kiejda KA, Morten B, Wong-Brown MW, Mathe A, Scott RJ, 'The relative mRNA expression of p53 isoforms in breast cancer is associated with clinical features and outcome.', Carcinogenesis, 35 586-596 (2014) [C1]
|
Nova | |||||||||
2013 |
Wong-Brown MW, McPhillips ML, Hipwell M, Pecenpetelovska G, Dooley S, Meldrum C, Scott RJ, 'cDNA analysis of the BRCA1 unclassified variant c.5194-12G \ A', CLINICAL GENETICS, 84 505-506 (2013) [C3]
|
Nova | |||||||||
2011 |
Zacharin M, Bajpai A, Chow CW, Catto-Smith A, Stratakis C, Wong-Brown M, Scott R, 'Gastrointestinal polyps in McCune Albright syndrome', Journal of Medical Genetics, 48 458-461 (2011) [C1]
|
Nova | |||||||||
2011 |
Kiejda KA, Wong-Brown M, Scott R, 'Genetic markers in breast cancer - How far have we come from BRCA1?', Asia-Pacific Journal of Molecular Medicine, 1 1-15 (2011) [C1]
|
Nova | |||||||||
2011 |
Wong-Brown M, Nordfors C, Mossman D, Pecenpetelovska G, Kiejda KA, Talseth-Palmer B, et al., 'BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer', Breast Cancer Research and Treatment, 127 853-859 (2011) [C1]
|
Nova | |||||||||
Show 22 more journal articles |
Conference (24 outputs)
Year | Citation | Altmetrics | Link | |||||
---|---|---|---|---|---|---|---|---|
2019 |
Wong-Brown MW, Lombard J, van der Westhuizen A, Bowden NA, 'Investigation of DNA Repair and the Epigenome in Chemoresistant High-Grade Serous Ovarian Cancer', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2019)
|
|||||||
2018 |
Mathe A, Wong-Brown M, Morten BC, Braye SG, Locke WJ, Stirzaker C, et al., 'Defining the Key Mediators of Breast Cancer Progression and Treatment Resistance in the triple Negative Subtype', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2018)
|
|||||||
2016 |
Mathe A, Wong-Brown M, Locke W, Stirzaker C, Braye S, Forbes J, et al., 'DNA METHYLATION PROFILE OF TRIPLE NEGATIVE BREAST CANCER-SPECIFIC GENES COMPARING LYMPH NODE POSITIVE PATIENTS TO LYMPH NODE NEGATIVE PATIENTS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2016)
|
|||||||
2015 |
Thompson E, Wong-Brown M, Rowley S, Dooley S, Li N, Hipwell M, et al., 'PANEL TESTING FOR BREAST CANCER RISK ASSESSMENT: IS IT JUST BECAUSE WE CAN RATHER THAN SHOULD?', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
|
|||||||
2015 |
Morten B, Wong-Brown M, Scott R, Avery-Kiejda K, 'ASSOCIATION OF THE POLYMORPHIC INTRON 3 16 BP DUPLICATION IN TP53 (RS17878362) WITH A LOW Delta 40P53:P53 RATIO AND BETTER OUTCOME IN BREAST CANCER', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
|
|||||||
2014 |
Morten B, Campbell HG, Brown MW, Mathe A, Braithwaite AW, Scott RJ, Kiejda KA, ' 40p53 regulation of estrogen responsiveness in breast cancer.', 16th International p53 Workshop Proceedings, Stockholm, Sweden (2014) [E3]
|
|||||||
2014 |
Avery-Kiejda KA, Morten B, Wong-Brown MW, Mathe A, Scott RJ, 'The relationship between p53 isoforms and prognosis in breast cancer.', The Australian Society for Medical Research (ASMR) Satellite Scientific Meeting Programme, Newcastle, NSW, Australia (2014) [E3]
|
|||||||
2014 |
Mathe A, Avery-Kiejda KA, Wong-Brown M, Morten B, Forbes JF, Braye SG, Scott RJ, 'IDENTIFICATION OF NOVEL TRANSCRIPTS SPECIFIC TO TRIPLE NEGATIVE BREAST CANCER THAT ARE ASSOCIATED WITH LYMPH NODE METASTASIS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
|
|||||||
2014 |
Mathe A, Avery-Kiejda KA, Wong-Brown M, Forbes JF, Braye SG, Scott RJ, 'Eight microRNAs as biomarkers for metastatic spread in triple negative breast cancer', EUROPEAN JOURNAL OF CANCER (2014) [E3]
|
|||||||
2014 |
Wong-Brown M, Scott RJ, 'Low prevalence of germline PALB2 mutations in Australian triple-negative breast cancer', Abstract booklet, Kingscliff (2014) [E3]
|
|||||||
2013 |
Mathe A, Avery-Kiejda KA, Wong-Brown MW, Forbes JF, Braye SG, Scott RJ, 'Target gene identification of microRNAs associated with lymph node metastases in triple negative breast cancer.', 25th Lorne Cancer Conference Proceedings, Lorne, VIC, Australia (2013) [E3]
|
|||||||
2013 |
Mathe A, Avery-Kiejda KA, Wong-Brown M, Forbes JF, Braye SG, Scott RJ, 'Integration of microRNA and gene expression profiling in triple negative breast cancer to identify possible biomarkers for metastases.', Breakthrough Breast Cancer TNBC Conference Proceedings, London, UK (2013) [E3]
|
|||||||
2013 |
Wong-Brown M, Li S, Wilkins M, Avery-Kiejda KA, Bowden N, Scott R, 'Targeted resequencing of BRCA1 and BRCA2 in familial breast cancer.', Kathleen Cunningham Foundation Consortium for Research into Familial Aspects of Cancer 2013 Research and Practice Proceedings, Cairns, QLD, Australia. (2013) [E3]
|
|||||||
2013 |
Wong-Brown M, Avery-Kiejda K, Bowden N, Scott R, 'Prevalence of BRCA1 and BRCA2 germline mutations in triple-negative breast cancer', Programme, Newcastle (2013) [E3]
|
|||||||
2013 |
Mathe A, Wong-Brown M, Forbes JF, Braye SG, Scott RJ, Avery-Kiejda KA, 'Identification of biomarkers for metastatic spread in triple negative breast cancer.', Translational Cancer Research Conference Abstract booklet, Newcastle, Australia (2013) [E3]
|
|||||||
2012 |
Wong-Brown M, Li S, Wilkins M, Kiejda KA, Bowden NA, Scott R, 'Exploratory targeted resequencing of BRCA1 and BRCA2 in inherited breast cancer', Programme. kConFab Familial Aspects of Cancer: Research & Practice 2012, Kingscliff, NSW (2012) [E3]
|
|||||||
2012 |
Gleeson M, Spigelman AD, Meldrum CJ, Dooley S, Wong-Brown M, Young B, et al., 'A case of two mutations in trans in a women diagnosed with breast cancer at the age of 3+0 years', Programme. kConFab Familial Aspects of Cancer: Research & Practice 2012, Kingscliff, NSW (2012) [E3]
|
|||||||
2012 |
Wong-Brown M, Li S, Wilkins M, Kiejda KA, Bowden NA, Scott R, 'Targeted resequencing of BRCA1 and BRCA2 in inherited breast cancer', Cancer Research, San Antonio, Texas (2012) [E3]
|
|||||||
2011 |
Wong-Brown M, Scott R, Hibberd A, Trevillian PR, Clark D, Meldrum C, 'Measurement of Foxp3 gene expression in renal transplant recipients', Immunology and Cell Biology, Canberra, Australia (2011) [E3]
|
|||||||
2010 |
Wong-Brown M, Bowden NA, Kiejda KA, Scott R, 'BRIP1 and PALB2 mutation detection in Hunter-New England familial breast cancer cohort', 27th HUGO-IABCR Congress 2010. Genomics, Biology and Breast Cancer Treatment. Programme & Abstract Book, Biopolis, Singapore (2010) [E3]
|
|||||||
2010 |
Wong-Brown M, Bowden NA, Forbes JF, Braye SG, Scott R, 'Microsatellite instability (I) in breast tumours', Sydney Cancer Conference 2010. Profiling Risk, Personalising Treatment and Predicting Outcomes. Conference Program and Abstract Book, Sydney, NSW (2010) [E3]
|
|||||||
Show 21 more conferences |
Grants and Funding
Summary
Number of grants | 23 |
---|---|
Total funding | $3,735,148 |
Click on a grant title below to expand the full details for that specific grant.
20233 grants / $57,832
Development of ovarian cancer detection test$39,332
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Doctor Michelle Brown, Professor Nikola Bowden |
Scheme | Research Grant |
Role | Lead |
Funding Start | 2023 |
Funding Finish | 2026 |
GNo | G2301073 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
Drug Repurposing in Treatment Resistant Ovarian Cancer$10,000
Funding body: Tour De Cure
Funding body | Tour De Cure |
---|---|
Project Team | Professor Nikola Bowden, Professor Nikola Bowden, Doctor Michelle Brown, Associate Professor Paul Tooney, Mr Bayley Matthews |
Scheme | PhD Support Scholarship |
Role | Investigator |
Funding Start | 2023 |
Funding Finish | 2023 |
GNo | G2201031 |
Type Of Funding | C1700 - Aust Competitive - Other |
Category | 1700 |
UON | Y |
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics$8,500
Funding body: Cancer Institute NSW
Funding body | Cancer Institute NSW |
---|---|
Project Team | Doctor Michelle Brown |
Scheme | Travel Grants |
Role | Lead |
Funding Start | 2023 |
Funding Finish | 2023 |
GNo | G2300347 |
Type Of Funding | C2400 – Aust StateTerritoryLocal – Other |
Category | 2400 |
UON | Y |
20222 grants / $500,000
Sartorious Incucyte SX5 Live-Cell Analysis Instrument for high throughput screening of drugs for repurposing as chemotherapy in the treatment of cancer$400,000
Funding body: Cancer Institute NSW
Funding body | Cancer Institute NSW |
---|---|
Project Team | Doctor Michelle Brown, Professor Nikola Bowden, Karen Briscoe, Professor Doan Ngo, Dr Frank Reimann, Professor Aaron Sverdlov |
Scheme | Research Equipment Grant |
Role | Lead |
Funding Start | 2022 |
Funding Finish | 2022 |
GNo | G2200706 |
Type Of Funding | C2300 – Aust StateTerritoryLocal – Own Purpose |
Category | 2300 |
UON | Y |
Drug Repurposing for Ovarian Cancer$100,000
Funding body: Maitland Cancer Appeal Committee Incorporated
Funding body | Maitland Cancer Appeal Committee Incorporated |
---|---|
Project Team | Professor Nikola Bowden, Professor Alister Page, Doctor Michelle Brown |
Scheme | Research Funding |
Role | Investigator |
Funding Start | 2022 |
Funding Finish | 2022 |
GNo | G2200742 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
20213 grants / $59,603
HMRI Researcher Bridging Funds$30,603
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Doctor Michelle Brown |
Scheme | Research Grant |
Role | Lead |
Funding Start | 2021 |
Funding Finish | 2021 |
GNo | G2100103 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
2022 Women in Research Fellowship$24,000
Funding body: The University of Newcastle - Research and Innovation Division
Funding body | The University of Newcastle - Research and Innovation Division |
---|---|
Project Team | Michelle Wong-Brown |
Scheme | Research Advantage Funding |
Role | Lead |
Funding Start | 2021 |
Funding Finish | 2022 |
GNo | |
Type Of Funding | Internal |
Category | INTE |
UON | N |
Pilot study to develop a program for drug repurposing in triple-negative breast cancer$5,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Doctor Michelle Brown |
Scheme | Research Grant |
Role | Lead |
Funding Start | 2021 |
Funding Finish | 2021 |
GNo | G2100096 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
20204 grants / $2,778,829
Australian Program for Drug Repurposing for Ovarian Cancer Treatment$2,736,499
Funding body: Department of Health and Aged Care
Funding body | Department of Health and Aged Care |
---|---|
Project Team | Professor Nikola Bowden, Professor Jennifer Martin, Doctor Michelle Brown, Associate Professor Deborah Marsh, Associate Professor Deborah Marsh, Caroline Ford, Dr David Thomas, Dr David Thomas, Emeritus Professor Richard Head, Ms Penny Reeves, Ms Gill Stannard |
Scheme | MRFF - EPCDR - Ovarian Cancer |
Role | Investigator |
Funding Start | 2020 |
Funding Finish | 2025 |
GNo | G2000012 |
Type Of Funding | C1300 - Aust Competitive - Medical Research Future Fund |
Category | 1300 |
UON | Y |
Testing of CSIRO technology to detect high grade serous ovarian cancer cells in blood samples$29,450
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Nikola Bowden, Distinguished Emeritus Professor John Aitken, Doctor Michelle Brown |
Scheme | Research Grant |
Role | Investigator |
Funding Start | 2020 |
Funding Finish | 2020 |
GNo | G2000097 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
A rapid approach to identifying chemoresistance in high-grade serous ovarian cancer$8,000
Funding body: Priority Research Centre for Drug Development
Funding body | Priority Research Centre for Drug Development |
---|---|
Project Team | Dr Michelle Wong-Brown, Dr Moira Graves, A/Prof Nikola Bowden |
Scheme | Priority Research Centre for Drug Development Seed Funding |
Role | Lead |
Funding Start | 2020 |
Funding Finish | 2020 |
GNo | |
Type Of Funding | Internal |
Category | INTE |
UON | N |
Small Equipment Grant Funding$4,880
Funding body: Priority Research Centre for Drug Development
Funding body | Priority Research Centre for Drug Development |
---|---|
Project Team | Dr Michelle Wong-Brown, Dr Moira Graves |
Scheme | Priority Research Centre for Drug Development Small Equipment Grant |
Role | Lead |
Funding Start | 2020 |
Funding Finish | 2020 |
GNo | |
Type Of Funding | Internal |
Category | INTE |
UON | N |
20194 grants / $161,806
Faculty of Health and Medicine Research Equipment Grant$79,000
Funding body: Faculty of Health and Medicine, University of Newcastle
Funding body | Faculty of Health and Medicine, University of Newcastle |
---|---|
Project Team | Michelle Wong-Brown |
Scheme | Faculty of Health and Medicine Research Equipment Grant |
Role | Lead |
Funding Start | 2019 |
Funding Finish | 2019 |
GNo | |
Type Of Funding | Internal |
Category | INTE |
UON | N |
Repurposing existing drugs to overcome ovarian cancer chemoresistance$67,806
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Nikola Bowden, Doctor Michelle Brown, Professor Jennifer Martin, Emeritus Professor Richard Head |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2019 |
Funding Finish | 2019 |
GNo | G1901179 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
DNA repair and drug repurposing: A rapid approach to develop new treatments for chemoresistant ovarian cancer$10,000
Funding body: Priority Research Centre for Chemical Biology and Clinical Pharmacology, UoN
Funding body | Priority Research Centre for Chemical Biology and Clinical Pharmacology, UoN |
---|---|
Project Team | Dr Michelle Wong-Brown, A/Prof Nikola Bowden |
Scheme | Priority Research Centre for Chemical Biology and Clinical Pharmacology Seed Grant |
Role | Lead |
Funding Start | 2019 |
Funding Finish | 2019 |
GNo | |
Type Of Funding | Internal |
Category | INTE |
UON | N |
Repurposing old drugs for new purpose: Enhancing chemotherapy response in ovarian cancer$5,000
Funding body: Faculty of Health and Medicine, University of Newcastle
Funding body | Faculty of Health and Medicine, University of Newcastle |
---|---|
Project Team | Michelle Wong-Brown, Nikola Bowden, Jenny Schneider, Peter Galettis, Jennifer Martin |
Scheme | Strategic Pilot Grant |
Role | Lead |
Funding Start | 2019 |
Funding Finish | 2019 |
GNo | |
Type Of Funding | Internal |
Category | INTE |
UON | N |
20184 grants / $125,259
Career Advancement Fellowship in Cancer Research$62,535
Funding body: Priority Research Centre for Cancer Research, Innovation and Translation
Funding body | Priority Research Centre for Cancer Research, Innovation and Translation |
---|---|
Scheme | Career Advancement Fellowship in Cancer Research |
Role | Lead |
Funding Start | 2018 |
Funding Finish | 2018 |
GNo | |
Type Of Funding | Aust Competitive - Commonwealth |
Category | 1CS |
UON | N |
Do white blood cells from the bone marrow play a role in regrowth of glioblastoma and can blocking their movement into the brain improve treatment?$30,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Doctor Moira Graves, Professor Nikola Bowden, Doctor Michelle Brown |
Scheme | Research Grant |
Role | Investigator |
Funding Start | 2018 |
Funding Finish | 2020 |
GNo | G1901577 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
Investigation of DNA repair and the epigenome in chemoresistant high grade serous ovarian cancer$18,253
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Nikola Bowden, Doctor Michelle Brown |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2018 |
Funding Finish | 2018 |
GNo | G1800025 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
Investigation of DNA repair and the epigenome in chemoresistant high grade serous ovarian cancer$14,471
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Nikola Bowden, Doctor Michelle Brown |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2018 |
Funding Finish | 2018 |
GNo | G1800026 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
20161 grants / $15,819
University of Newcastle Researcher Equipment Grant$15,819
Funding body: The University of Newcastle, Australia
Funding body | The University of Newcastle, Australia |
---|---|
Project Team | Doctor Michelle Brown, Doctor Natalie Beveridge, Doctor Vicki Maltby, Doctor Moira Graves, and Doctor Katherine Bolton |
Scheme | Research Advantage Early Career Researcher Equipment Grant |
Role | Lead |
Funding Start | 2016 |
Funding Finish | 2017 |
GNo | |
Type Of Funding | External |
Category | EXTE |
UON | N |
20142 grants / $36,000
Targeted next-generation sequencing of potential breast cancer susceptibility genes$30,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Doctor Michelle Brown, Professor Rodney Scott |
Scheme | Bridging Grant |
Role | Lead |
Funding Start | 2014 |
Funding Finish | 2014 |
GNo | G1301293 |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | Y |
Karen Brown Breast Cancer Research Travel Grant$6,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Doctor Michelle Brown |
Scheme | Karen Brown Breast Cancer Research Travel Grant |
Role | Lead |
Funding Start | 2014 |
Funding Finish | 2014 |
GNo | G1401509 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
Research Supervision
Number of supervisions
Current Supervision
Commenced | Level of Study | Research Title | Program | Supervisor Type |
---|---|---|---|---|
2023 | PhD | Development of Ovarian Cancer Detection Test | PhD (Medicine), College of Health, Medicine and Wellbeing, The University of Newcastle | Principal Supervisor |
2021 | PhD | Drug Repurposing for Treatment-Resistant Ovarian Cancer | PhD (Medicine), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
Research Collaborations
The map is a representation of a researchers co-authorship with collaborators across the globe. The map displays the number of publications against a country, where there is at least one co-author based in that country. Data is sourced from the University of Newcastle research publication management system (NURO) and may not fully represent the authors complete body of work.
Country | Count of Publications | |
---|---|---|
Australia | 35 | |
China | 6 | |
Canada | 5 | |
Poland | 2 | |
Sweden | 2 | |
More... |
Dr Michelle Brown
Positions
Postdoctoral Researcher
Centre for Drug Repurposing and Medicines Research (CDRMR)
School of Medicine and Public Health
College of Health, Medicine and Wellbeing
Casual Lecturer
Centre for Drug Repurposing and Medicines Research (CDRMR)
School of Biomedical Sciences and Pharmacy
College of Health, Medicine and Wellbeing
Focus area
Medical Genetics
Contact Details
michelle.wong-brown@newcastle.edu.au | |
Phone | (02) 4042 0321 |
Fax | (02) 4042 0031 |
Links |
Twitter Research Networks Google+ |
Office
Room | HMRI Level 3 West |
---|---|
Building | Hunter Medical Research Institute |
Location | Hunter Medical Research Institute , |